Skip to main content
SpringerLink
Log in

Onkologie: Dickdarm

  • Conference paper
Book cover Handbuch Gastroenterologie 2010

Part of the book series: Handbuch Update-Seminar ((UPDATESEMINAR))

  • 1085 Accesses

Zusamenfassung

Jedes Jahr führt die American Society of Clinical Oncology (ASCO) die Forschungsergebnisse auf, die eine weitreichende zukünftige Bedeutung haben werden (1). Im Bereich der palliativen Chemotherapie wird die molekulare Selektion anhand des KRAS Mutationsstatus hervorgehoben. Interessant ist es zu sehen, dass auch in den USA über finanzielle Limitationen der Drittmittelförderung geklagt wird. Es wird prognostiziert, dass in den Vereinigten Staaten ein Mangel an Onkologen im Jahr 2020 auftreten wird. Der Mehrbedarf wird mit 4.000 Onkologen veranschlagt. Erstaunlich ist, dass auch in den USA zu wenige Patienten in klinische Therapiestudien eingebracht werden (geschätzt > 5% aller Tumorpatienten). Also auch in der Onkologie: Aspekte der Globalisierung im Bereich der Nachwuchs- und Studienpatienten-rekrutierung!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

11.15 Literatur

  1. Winer E, Gralow J, Diller L, et al. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention and screening — a report from the American Society of Clinical Oncology. J Clin Oncol 2008;27:812–826.

    Article  PubMed  Google Scholar 

  2. Booth CM, Cescon DW, Wang L, et al. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2009;26:5458–5464.

    Article  Google Scholar 

  3. Martinez ME, Baron JA, Liebermann DA, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136:832–841.

    Article  PubMed  Google Scholar 

  4. Laiyemo AO, Pinsky PF, Marcus PM, et al. Utilization and yield of surveillance colonoscopy in the continued follow-up study of the Polyp Prevention Trial. Clin Gastroenterol Hepatol 2009;7:562–567.

    Article  PubMed  Google Scholar 

  5. Laiyemo AO, Murphy G, Sansbury LB, et al. Hyperplastic polyps and the risk of adenoma recurrence in the Polyp Prevention Trial. Clin Gastroenterol Hepatol 2009;7:192–197

    Article  PubMed  Google Scholar 

  6. Mutch MG, Schoen RE, Fleshman JW. et al. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 2009;7:568–574.

    Article  PubMed  Google Scholar 

  7. Wong NACS, Hunt LP, Novelli MR, et al. Observer agreement in the diagnosis of serrated polyps of the large bowel. Histopathology 2009;55:63–66.

    Article  PubMed  Google Scholar 

  8. Chan MY, Cohen H, Spiegel BMR. Fewer polyps detected by colonoscopy as the day progresses at a veteran’s administration teaching hospital. Clin Gastroenterol Hepatol 2009;7:1217–1223.

    Article  PubMed  Google Scholar 

  9. Boparei KS, Decker E, Van Eeden S, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 2008;135:2014–2018.

    Article  Google Scholar 

  10. Lepistö A, Kiviluoto T, Halttunen J, Järvinen J. Surveillance and treatment of duodenal adenomatosis in familial adenomatous polyposis. Endoscopy 2009;41:504–509.

    Article  PubMed  Google Scholar 

  11. Jones N, Vogt S, Nielsen M, et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009;137:489–494.

    Article  PubMed  Google Scholar 

  12. Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009;27:3975–3980.

    Article  CAS  PubMed  Google Scholar 

  13. Hüneburg R, Lammert F, Rabe C. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009;41:316–322.

    Article  PubMed  Google Scholar 

  14. Lang K, Lines LM, Lee DW, et al. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-medicare data. Clin Gastroenterol Hepatol 2009;7:198–204.

    Article  PubMed  Google Scholar 

  15. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009;100:611–616.

    Article  CAS  PubMed  Google Scholar 

  16. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer 2009;101:256–266.

    Article  CAS  Google Scholar 

  17. Kube R, Ptok H, Wolff S, Lippert H. Quality of medical care in colorectal cancer in Germany. Onkologie 2009;32:25–29.

    Article  PubMed  Google Scholar 

  18. Liebig C, Ayala G, Wilks J, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009;27:5131–5137.

    Article  PubMed  Google Scholar 

  19. Cohen SJ, Punt CJA, lanotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncology 2009;20:1223–1229.

    Article  CAS  Google Scholar 

  20. Chang GJ, Hu CY, Eng C, et al. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 2009;27:5938–5943.

    Article  PubMed  Google Scholar 

  21. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1–8.

    PubMed  Google Scholar 

  22. Brenner H, Hoffmeister M, Brenner G, et al. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer 2009;doi:10.1016/j.ejca.2009.,02017.

    Google Scholar 

  23. Sawhney MS, Cury MS, Neeman N, et al. Effect of institution-wide police of colonoscopy withdrawal time ≥7 minutes on polyp detection. Gastroenterology 2008;135:1892–1898.

    Article  PubMed  Google Scholar 

  24. Rabeneck L, Paszat LF, Hilsden J, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008;135:1899–1906.

    Article  PubMed  Google Scholar 

  25. Mansmann U, Crispin A, Henschel V, et al. Epidemiology and quality control of 245000 outpatient colonoscopies. Dtsch Ärztebl Int 2008;105:434–440.

    PubMed  Google Scholar 

  26. Bokemeyer B, Bock H, Hüppe D, et al. Screening colonoscopy for colorectal cancer prevention: results from a German online registry on 269000 cases. Eur J Gastroenterol Hepatol 2009;21:650–655.

    Article  PubMed  Google Scholar 

  27. Paggi S, Radaelli F, Amato A, et al. The impact of narrow band imaging in screening colonoscopy: a randomized controlled trial. Clin Gastroenterol Hepatol 2009;7:1049–1054.

    Article  PubMed  Google Scholar 

  28. Borg BB, Gupta NK, Zuckerman GR, et al. Impact of obesity on bowel preparation for colonoscopy. Clin Gastroenterol Hepatol 2009;7:670–675.

    Article  PubMed  Google Scholar 

  29. Brenner H, Haug U, Arndt V, et al. Low risk of colorectal cancer and advanced adenomas more than 10 years after negative colonoscopy. Gastroenterology 2009;DOI:10.1053/j. gastro. 2009.10.054.

    Google Scholar 

  30. Brackmann S, Andersen SN, Aamodt G. et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009;44:46–55.

    Article  PubMed  Google Scholar 

  31. Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009;136:1561–1567.

    Article  PubMed  Google Scholar 

  32. Lutgens MWMD, Vleggaar FP, Schipper MEI, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008;57:1246–1251.

    Article  CAS  PubMed  Google Scholar 

  33. Van den Broek FJC, Fockens P, Van Eeden S, et al. Clinical evaluation of endoscopic trimodal imaging for the detection and differentiation of colonic polyps. Clin Gastroenterol Hepatol 2009;7:288–295.

    Article  PubMed  Google Scholar 

  34. Wong JCH, Yau KK, Cheung HYS, et al. Towards painless colonoscopy: a randomized controlled trial on carbon dioxide-insufflating colonoscopy. ANZ J Surg 2008;78:871–874.

    Article  PubMed  Google Scholar 

  35. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872–877.

    Article  PubMed  Google Scholar 

  36. Haller D, Tabernero J, Maroun J, et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur J Cancer Suppl 2009;7:4.

    Article  Google Scholar 

  37. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102–109.

    Article  CAS  PubMed  Google Scholar 

  38. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–3116.

    Article  CAS  PubMed  Google Scholar 

  39. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117–3125.

    Article  PubMed  Google Scholar 

  40. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomized trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncology 2009;20:674–680.

    Article  CAS  Google Scholar 

  41. Fields A, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009;27:1941–1947.

    Article  CAS  PubMed  Google Scholar 

  42. Allegra J, Yother G, O’Connel MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; DOI/10.1200/JCO. 2009.21.9220.

    Google Scholar 

  43. Wolmark N, Yothers G, O’Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009 (suppl;abstr. LBA4); 27:18s.

    Google Scholar 

  44. Bertagnolli MM, Niedzwiecki D, Comptom CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia group B protocol 89803. J Clin Oncol 2009;27:1814–1821.

    Article  CAS  PubMed  Google Scholar 

  45. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 2009 (suppl; abstr 4001); 27:15s.

    Google Scholar 

  46. Etzioni DA, El-Khoueiry AB, Beart RW. Rates and predictors of chemotherapy use for stage III colon cancer. Cancer 2008;113:3279–3289.

    Article  PubMed  Google Scholar 

  47. McCleary NA, Meyerhardt J, Green E et al. Impact of older age on the efficacy of newer adjuvant therapies in > 12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2009 (suppl; abstr 4010) 27:15s.

    Article  Google Scholar 

  48. Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases. Cancer 2009;115:752–759.

    Article  PubMed  Google Scholar 

  49. Kopetz S, Chang GJ, Overmann MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–3683.

    Article  PubMed  Google Scholar 

  50. Adam R, Wiecherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver métastases: is there a possibility of cure? J Clin Oncol 2009;27:1829–1835.

    Article  PubMed  Google Scholar 

  51. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20:985–992.

    Article  CAS  PubMed  Google Scholar 

  52. Folprecht G, Gruenberger J, Hartmann T et al. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM study). Gastrointestinal Cancers Symposium, 2009; No. 296.

    Google Scholar 

  53. Gunderson LL, Callister M, Marschke R, et al. Stratification of rectal cancer for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res 2008;2:25–33.

    PubMed  Google Scholar 

  54. Ceelen W, Fierens K, Niewenhove YV, et al. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer 2009;124:2966–2972.

    Article  CAS  PubMed  Google Scholar 

  55. Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of rectum: NSABP R-03. J Clin Oncol 2009;27:5124–5130.

    Article  PubMed  Google Scholar 

  56. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008;26:3687–3694.

    Article  CAS  PubMed  Google Scholar 

  57. Sebag-Montefiore D, Stephens RJ, Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR 07 and Nl-CIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811–820.

    Article  PubMed  Google Scholar 

  58. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR 07 and NCIC-CTG C016 randomised clinical trial. Lancet 2009;373:821–828.

    Article  PubMed  Google Scholar 

  59. Rödel C, Sauer R, Fietkau R. Die Rolle der Magnetresonanztomographie für die Indikationsstellung zur präoperativen Therapie beim Rektumkarzinom. Strahlenther Oncol 2009;185:488–492.

    Article  Google Scholar 

  60. Wong YN, Meropol NJ, Speier W, et al. Cost implication of new treatments for advanced colorectal cancer. Cancer 2009;115:2081–2091.

    Article  CAS  PubMed  Google Scholar 

  61. Sargent J, Könne KH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first line treatment trials using individual data from patients with metastasic colorectal cancer J Clin Oncol 2009;27:1948–1955.

    Article  PubMed  Google Scholar 

  62. Poultsides GA, Servias EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronus stage IV colorectal cancer receiving combination Chemotherapie without surgery as initial treatment. J Clin Oncol 2009;27:3379–3384.

    Article  PubMed  Google Scholar 

  63. Byström P, Berglund A, Garske, Jacobsson H, et al. Early prediction of response to first-line chemotherapy by sequential (18F)-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009;20:157–1061.

    Google Scholar 

  64. Chibaudel B, Maindrault-Goebel F, Liedo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer?. The GERCOR OPTIMOX2 study. J Clin Oncol 2009;27:5727–5733.

    Article  CAS  PubMed  Google Scholar 

  65. Adams R, Wilson R, Seymour MT, et al. Intermittend versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). Eur J Cancer Suppl. 2009;7:3.

    Google Scholar 

  66. Van Cutsem E, Könne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 2009;360:1404–1417.

    Google Scholar 

  67. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663–671.

    Article  CAS  PubMed  Google Scholar 

  68. Van Cutsem E, Rougier P, Köhne C, et al. A meta-analysis of CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st line treatment for pati-ents (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutations status. Europ J Cancer Suppl. 2009;7:345.

    Article  Google Scholar 

  69. Maughan T, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Europ J Cancer Suppl 2009;7:4.

    Article  Google Scholar 

  70. Douillard J, Cassidy SJ, Tabernero J, et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. European J Cancer Suppl. 2009;7:6.

    Article  Google Scholar 

  71. Peeters M, Price T, Hotko Y, et al. Randomized phase 3 study of panitumab with FOLFIRI vs. FOLFIRI alone as second line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Europ J Cancer Suppl 2009;7:9.

    Google Scholar 

  72. Peeters M, Siena S, van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544–1554.

    Article  CAS  PubMed  Google Scholar 

  73. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705–5712.

    Article  PubMed  Google Scholar 

  74. Loupakis F, Pollina L, Stasi I, et al. PTEN Expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622–2629.

    Article  CAS  PubMed  Google Scholar 

  75. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924–5930.

    Article  CAS  PubMed  Google Scholar 

  76. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF Mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931–5937.

    Article  CAS  PubMed  Google Scholar 

  77. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical applications of patient selection. J Clin Oncol 2009;27:1130–1136.

    Article  CAS  PubMed  Google Scholar 

  78. Allegra CJ, Jessup JM, Somerfield MR. et. al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091–2096.

    Article  PubMed  Google Scholar 

  79. Cennamo V, Fuccio L, Mutri V, et al. Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy? Clin Gastroenterol Hepatol 2009;7:1174–1176.

    Article  PubMed  Google Scholar 

  80. Scartozzi M, Galizia E, Chiorrini A, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227–230.

    Article  CAS  PubMed  Google Scholar 

  81. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2008;27:199–205.

    Article  PubMed  Google Scholar 

  82. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevazizumab and cetuximab in metastatic colorectal cancer. N Eng J Med 2009;69:563–572.

    Article  Google Scholar 

  83. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2008;27:672–680.

    Article  PubMed  Google Scholar 

  84. Bidard FC, Tournigand C, Andre T, et al. Efficacy of FOFIRI-3 (Irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 2009;20:1042–1047.

    Article  PubMed  Google Scholar 

  85. Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with flourouracil: N9841. J Clin Oncol 2009;27:2848–2854.

    Article  CAS  PubMed  Google Scholar 

  86. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intaperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681–685.

    Article  PubMed  Google Scholar 

  87. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotatic body radiotherapy of liver métastases. J Clin Oncol 2009;27:1585–1591.

    Article  PubMed  Google Scholar 

  88. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic métastases using Yttrium-90 microspheres. Cancer 2009;115:1849–1858.

    Article  PubMed  Google Scholar 

  89. van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using Yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009;27:4089–4095.

    Article  PubMed  Google Scholar 

  90. Vente MAD, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009;19:951–959.

    Article  CAS  PubMed  Google Scholar 

  91. Tsikitis VL, Malireddy K, Green EA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the Clinical Outcomes of Surgical Therapy trial. J Clin Oncol 2009;27:3671–3676.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zentrum fur Innere Medizin, Klinikum Bremen-Ost, Zuricher Straße 40, 28325, Bremen, Deutschland

    Prof. Dr. Rainer Porschen

Authors
  1. Prof. Dr. Rainer Porschen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kiinik für Aiigemein- und Viszeraichirurgie, Dr. Horst Schmidt Kiiniken GmbH, Ludwig-Erhard-Straße 100, 65199, Wiesbaden

    Christian Eli

  2. Medizinische Klinik, Israelitisches Krankenhaus, Orchideenstieg 14, 22297, Hamburg

    Peter Layer

  3. II. Medizinische Kiinik, Kiinikum Aschaffenburg, Am Hasenkopf 1, 63739, Aschaffenburg

    Wolfgang Fischbach

  4. Chirurgisches Zentrum Viszeral-, Gefäß- und Endokrine Chirurgie, HELlOS Kiinikum Wuppertal, Heusnerstraße 40, 42283, Wuppertai

    Hubert Zirngibl

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Medizin Verlag Heidelberg

About this paper

Cite this paper

Porschen, R. (2010). Onkologie: Dickdarm. In: Eli, C., Layer, P., Fischbach, W., Zirngibl, H. (eds) Handbuch Gastroenterologie 2010. Handbuch Update-Seminar. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11635-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11635-3_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11634-6

  • Online ISBN: 978-3-642-11635-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation